Kintsugi is deep learning AI that identifies mental health conditions with signal processing from voice biomarkers, built on an API platform that enables partners to seamlessly screen, triage, treat, and monitor those in need. From payers in closing quality and patient experience gaps to health systems reducing readmissions to pharma in improving medication adherence, Kintsugi Voice is a real-time data layer that enables faster access to care.

Kintsugi Voice only needs 30 seconds of free-form speech to identify depression and anxiety, analyzing acoustic features of speech, not what is being said. Kintsugi Voice is:

• Reliable, objective and bias-free. 2x positive identification model performance compared to standard of care PHQ-2; 91% Sensitivity for Severe Depression. Kintsugi Voice is language agnostic, with the category’s largest proprietary dataset representing 250+ nationalities.

• Trusted. Clinically validated and FDA De Novo clearance ready. Deployed across call center, telehealth, and digital workflows to help payers, providers, and pharma close quality gaps, increase treatment adherence, and improve patient/clinician experience with a 4-6x ROI.

• Safe. SOC 2 Type 2 and HIPAA compliant as a Class II Software as a Medical Device.

• Recognized as an industry leader by the World Economic Forum, Fierce 15, Forbes AI150, Milken Institute, Gartner, National Science Foundation, and Frost & Sullivan.

To learn more please visit us at kintsugihealth.com.